Ensysce Biosciences director Curtis Rosebraugh resigns
Ensysce Biosciences Inc. reported that board member Dr. Curtis Rosebraugh resigned from its Board of Directors, effective April 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Ensysce Biosciences Inc. reported that board member Dr. Curtis Rosebraugh resigned from its Board of Directors, effective April 1, 2026. He also stepped down from the Board’s Nominating and Corporate Governance Committee. His written resignation notice is included as Exhibit 17 to the report.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Resignation effective date: April 1, 2026
Exhibit number: Exhibit 17
Company address ZIP code: 92037
3 metrics
Resignation effective date
April 1, 2026
Effective date of Dr. Curtis Rosebraugh’s board resignation
Exhibit number
Exhibit 17
Resignation notice attached to the report
Company address ZIP code
92037
ZIP code of Ensysce Biosciences’ principal executive offices in La Jolla, California
Key Terms
Nominating and Corporate Governance Committee, Emerging growth company, resignation notice, Inline XBRL
4 terms
Nominating and Corporate Governance Committee financial
"Until his resignation, Dr. Rosebraugh served as a member of the Nominating and Corporate Governance Committee"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Emerging growth company regulatory
"Securities registered pursuant to Section 12(b) of the Act ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
resignation notice financial
"the Company received a resignation notice, dated and effective April 1, 2026"
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Ensysce Biosciences (ENSC) disclose on April 3, 2026?
Ensysce Biosciences disclosed that board member Dr. Curtis Rosebraugh resigned from its Board of Directors, effective April 1, 2026. The filing also notes that he left his role on the Nominating and Corporate Governance Committee at the same time.
When did Ensysce Biosciences (ENSC) director Curtis Rosebraugh’s resignation take effect?
The resignation of Dr. Curtis Rosebraugh from Ensysce Biosciences’ Board of Directors was effective on April 1, 2026. The company received a formal resignation notice dated the same day and later filed the change in a current report.
Which Ensysce Biosciences (ENSC) board committee was affected by the resignation?
Dr. Curtis Rosebraugh’s departure affected the Nominating and Corporate Governance Committee of Ensysce Biosciences’ Board. Until his resignation, he served as a member of this committee, which typically oversees director nominations and corporate governance practices.
Is Curtis Rosebraugh’s resignation letter available to Ensysce Biosciences (ENSC) investors?
Yes. Ensysce Biosciences attached Dr. Curtis Rosebraugh’s resignation notice as Exhibit 17 to the report. Investors can review this exhibit to see the exact language and terms of his resignation from the Board of Directors.
Who signed the Ensysce Biosciences (ENSC) report announcing the board resignation?
The report announcing Dr. Curtis Rosebraugh’s resignation was signed by Dr. Lynn Kirkpatrick, Ensysce Biosciences’ President and Chief Executive Officer. Her signature indicates the filing was authorized on behalf of the company’s management.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates